Lab21 Announces Licence Agreement with Ark Therapeutics for Predictive Coronary Heart Disease Diagnostic

15-Oct-2007 - Lab 21 announced that it has entered into an exclusive license with Ark Therapeutics of a diagnostic test to measure autoantibodies to oxidized low density lipoprotein (oxLDL), which is a predictive risk factor for the development of coronary heart disease (CHD). The oxLDL test can identify ...

Ark Therapeutics Group plc: European Patent Granted for Cerepro

17-Oct-2006 - Ark Therapeutics Group plc announced that the European Patent Office has granted the Company a patent covering the use of Cerepro, its novel gene-based medicine for the treatment of operable high grade glioma (brain cancer). The patent grant gives protection in Europe until November 2019. Cerepro ...

Breakthrough at Ark opens way to reduce side-effects and increase efficacy of anti-cancer therapies

Unique DNA-based targeting technology Scavidin halts tumour progression with one-tenth of conventional chemotherapy dose

22-Feb-2006 - Ark Therapeutics Group plc announced that its novel gene-based drug targeting platform technology, Scavidin(R) has been shown to be highly effective in stopping tumour development in two cancer treatment models, using low doses of existing anti-cancer agents which would be sub-therapeutic if ...

Ark Therapeutics Study Confirms Therapeutic Effect of Vitor(TM) in Cancer Cachexia

18-Jan-2006 - Ark Therapeutics Group plc announced the full analysis from the first safety and efficacy study of Vitor(TM) in cancer cachexia. The results are consistent with the preliminary results previously announced on 28 October 2005 and provide additional statistical confirmation. The study examined ...

Ark Therapeutics receives EUR2.19 million grant for new manufacturing facility in Finland

Largest ever grant awarded to biotechnology company by TE-Centre

07-Nov-2005 - Ark Therapeutics Group plc announced that it has been awarded a grant of EUR2.19 million to support the Company's investment in a new GMP manufacturing facility (MT4) in Kuopio, Finland. The grant is from The Employment and Economic Development Centre of Finland ("TE-Centre") and is believed to ...

Ark receives licence to manufacture first gene medicine for commercial supply

24-Oct-2005 - Ark Therapeutics Group plc announced that, following an inspection by the Finnish National Agency for Medicines, on behalf of the European Medicines Agency (EMEA), its facility in Kuopio, Finland has received Good Manufacturing Practice (GMP) Certification to manufacture commercial supplies of ...

Ark makes breakthrough in targeted gene therapy delivery

Avoids harmful consequences of therapeutic gene being inserted in wrong place

09-Aug-2005 - Ark Therapeutics Group plc announceds that its scientists in Finland have discovered a novel gene therapy delivery technology which selectively inserts DNA into the specific therapeutic site in the genome (targeted integration). This technology is the subject of an Ark PCT filing. The existing ...

Ark Granted Patent in Europe for Trinam®

25-Jan-2005 - Ark Therapeutics Group plc announced that it has been issued with a patent by the European Patent Office for Trinam®, its novel therapy to prevent blood vessels blocking after vascular graft access surgery. Subject to the payment of renewal fees, this patent can be maintained until at least ...